The effect of PPAR-γ agonist on 18F-FDG PET imaging for differentiating tumors and inflammation lesions

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 85-91

  Cheong, Su Jin ^a   Lee, Chang Moon ^b   Kim, Eun Mi ^a   Lim, Seok Tae ^a   Sohn, Myung Hee ^a   Jeong, Hwan Jeong ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

18F FDG PET; Inflammation; Pioglitazone; PPAR ; Tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; GLUCOSE; GLUCOSE TRANSPORTER 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CELL LINE; DISEASE MODEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; KB CELL LINE; MACROPHAGE; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR XENOGRAFT; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; SCINTISCANNING; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANILIDES; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 84921348794     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.08.013     Document Type: Article

References (27)

1. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26:244-251.
2. Kota B.P., Huang T.H., Roufoqalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94.
3. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activator receptors. Pharmacol Rev 2006, 58:726-741.
4. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302:93-109.
5. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10:245-257.
6. Reilly S.M., Lee C.H. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 2008, 582:26-31.
7. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002, 168:2795-2802.
8. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
9. Kieć-Wilk B., Dembińska-Kieć A., Olszanecka A., Bodzioch M., Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol 2005, 56:149-162.
10. Fürnsinn C., Waldhäusl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002, 45:1211-1223.
11. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002, 18:10-15.
12. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000, 278:704-711.
13. Kudzma D.J. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus. Am J Manag Care 2002, 8:472-482.
14. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
15. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
16. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
17. Kapucu L.O., Meltzer C.C., Townsend D.W., Keenan R.J., Luketich J.D. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998, 39:1267-1269.
18. Goo J.M., Im J.G., Do K.H., Yeo J.S., Seo J.B., Kim H.Y., et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000, 216:117-121.
19. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003, 44:540-548.
20. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006, 47:633-638.
21. Kubota R., Kubota K., Yamada S., Tada M., Ido T., Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994, 35:104-112.
22. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992, 33:1972-1980.
23. Kim S.L., Kim E.M., Cheong S.J., Lee C.M., Kim D.W., Jeong H.J., et al. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells. Nucl Med Biol 2009, 36:427-433.
24. Marom E.M., Aloia T.A., Moore M.B., Hara M., Herndon J.E., Harpole D.H., et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 2001, 33:99-107.
25. Tian M., Zhang H., Nakasone Y., Mogi K., Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Mol Imaging 2004, 31:5-12.
26. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwartz J.L. Validation of FLT uptakes as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002, 43:1210-1217.
27. 18F-FDG. J Nucl Med 2003, 44:1426-1431.